Clinical pharmacokinetics of simotinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC patients.

被引：1
|
作者：
Han, Xiaohong
Li, Ning
Hu, Xingsheng
Song, Yuanyuan
Zhang, Yan
Shi, Yuankai
机构：
[1] Chinese Acad Med Sci, Canc Inst Hosp, Dept Med Oncol, Beijing 100730, Peoples R China
[2] Peking Union Med Coll, Beijing 100021, Peoples R China
[3] Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China
[4] Chinese Acad Med Sci, Canc Inst Hosp, Beijing 100730, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e13575
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13575
引用
收藏
页数：1
相关论文
共 50 条
  • [31] EGFR MUTATION AND TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN A DANISH (CAUCASIAN) POPULATION OF ADVANCED NSCLC PATIENTS AT ODENSE UNIVERSITY HOSPITAL 2010-11
    Kjeldsen, R.
    Hansen, K. H.
    Olsen, K. E.
    Hansen, N. G.
    Hansen, O.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S66 - S67
  • [32] Advanced NSCLC with EGFR Mutations in Elderly Patients. Single-Center Experience
    Artal Cortes, A.
    Torres, I.
    Alvarez, M.
    Comin, A.
    Felices, P.
    Nuno, A.
    Gurruchaga, I.
    Marquez, D.
    Vinaras, A.
    Hernando, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2226 - S2226
  • [33] Clinical outcomes of patients with advanced NSCLC with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors
    Gu, Yangchun
    Yu, JinYu
    Hu, Haifeng
    Zhang, Hua
    Cao, Baoshan
    Liang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)
    Popat, Sanjay
    Hsia, Te-Chun
    Hung, Jen-Yu
    Jung, Hyun Ae
    Shih, Jin-Yuan
    Park, Cheol Kyu
    Lee, Seung Hyeun
    Okamoto, Tatsuro
    Ahn, Hee Kyung
    Lee, Yong Chul
    Sato, Yuki
    Lee, Sung Sook
    Mascaux, Celine
    Daoud, Hasan
    Marten, Angela
    Miura, Satoru
    ONCOLOGIST, 2022, 27 (04): : 255 - 265
  • [35] Aggressive progression to EGFR tyrosine kinase inhibitors in advanced NSCLC patients: concomitant mutations, prognostic indicator and subsequent management
    Wen, Ruishan
    Chen, Ying
    Long, Jinyu
    Huang, Xiulian
    Guo, Yuxin
    Lin, Baoquan
    Yu, Zongyang
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (11) : 8307 - 8316
  • [36] EGFR, KRAS, PIK3CA MUTATIONS AND RESPONSE TO TYROSINE KINASE INHIBITORS (TKIS) IN ADVANCED NSCLC PATIENTS
    Chiari, Rita
    Ludovini, Vienna
    Bianconi, Fortunato
    Pistola, Lorenza
    Colella, Renato
    Mameli, Mariagrazia
    Giuffrida, Dario
    Tofanetti, Francesca Romana
    Flacco, Antonella
    Crino, Lucio
    ANNALS OF ONCOLOGY, 2009, 20
  • [37] EGFR, KRAS, PIK3CA mutations and response to tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients
    Ludovini, Vienna
    Bianconi, Fortunato
    Pistola, Lorenza
    Chiari, Rita
    Minotti, Vincenzo
    Colella, Renato
    Mameli, Maria G.
    Giuffrida, Dario
    Tofanetti, Francesca R.
    Flacco, Antonella
    Cavaliere, Antonio
    Crino, Lucio
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S676 - S676
  • [38] EGFR, KRAS, PIK3CA mutations and response to tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients
    Darwish, S.
    Ludovini, V.
    Pistola, L.
    Bianconi, F.
    Betti, M.
    Chiari, R.
    Sidoni, A.
    Giuffrida, D.
    Tofanetti, F. R.
    Flacco, A.
    Crino, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] EGFR, KRAS, PIK3CA mutations and response to tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients
    Chiari, R.
    Ludovini, V.
    Bianconi, F.
    Pistola, L.
    Colella, R.
    Mameli, M.
    Giuffrida, D.
    Tofanetti, F. R.
    Flacco, A.
    Crino, L.
    EJC SUPPLEMENTS, 2009, 7 (02): : 554 - 554
  • [40] EGFR, KRAS, PIK3CA MUTATIONS AND RESPONSE TO TYROSINE KINASE INHIBITORS (TKIS) IN ADVANCED NSCLC PATIENTS
    Crino, L.
    Pistola, L.
    Bianconi, F.
    Chiari, R.
    Meacci, M.
    Colella, R.
    Giuffrida, D.
    Tofanetti, F. R.
    Flacco, A.
    Ludovini, V.
    LUNG CANCER, 2009, 64 : S54 - S54
12345